RYTMRhythm PharmaceuticalsRYTM info
$56.12info1.15%24h
Global rank3655
Market cap$3.32B
Change 7d2.65%
YTD Performance24.60%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Rhythm Pharmaceuticals (RYTM) Stock Overview

    Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

    RYTM Stock Information

    Symbol
    RYTM
    Address
    222 Berkeley StreetBoston, MA 02116United States
    Founded
    -
    Trading hours
    -
    Website
    https://rhythmtx.com
    Country
    🇺🇸 United States
    Phone Number
    857 264 4280

    Rhythm Pharmaceuticals (RYTM) Price Chart

    -
    Value:-

    Rhythm Pharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $56.12
    N/A
    Market Cap
    $3.32B
    N/A
    Shares Outstanding
    59.10M
    N/A
    Employees
    177.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org